Leveraging Medical Robotics Heritage, the Company Expands into Consumer Market, Envisioning Exoskeletons as Integral ‘New Organs’ LAS VEGAS, Jan. 9, 2026 /PRNewswireLeveraging Medical Robotics Heritage, the Company Expands into Consumer Market, Envisioning Exoskeletons as Integral ‘New Organs’ LAS VEGAS, Jan. 9, 2026 /PRNewswire

From Clinical Recovery to Lifelong Empowerment: RoboCT Showcases Integrated Ecosystem Strategy at CES 2026

2026/01/10 04:30
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Leveraging Medical Robotics Heritage, the Company Expands into Consumer Market, Envisioning Exoskeletons as Integral ‘New Organs’

LAS VEGAS, Jan. 9, 2026 /PRNewswire/ — At CES 2026, RoboCT is presenting a comprehensive vision that extends far beyond single products. The Chinese exoskeleton leader is outlining its strategic blueprint to build a full-lifecycle mobility ecosystem, anchored by its innovative “Rehabilitation-as-a-Service” (RaaS) model and a vision for exoskeletons as augmentative human “new organs.”

“CES marks our strategic transition from a focused medical device innovator to an enabler of human mobility across the lifespan and scenarios,” stated Dr. WANG Tian, Founder and CEO of RoboCT. “We are showcasing not just the GoGo product line, but an integrated system where hardware, data, and professional services converge to deliver continuous, personalized support from hospital to home.”

The cornerstone of this ecosystem is RoboCT’s pioneering RaaS model. This platform integrates exoskeleton devices with a cloud-based intelligence center, enabling real-time data monitoring, remote therapist oversight, and personalized training program adjustments. This digital continuum breaks down the walls of the rehabilitation clinic, allowing for professional-grade recovery and support to extend seamlessly into community and home settings, improving accessibility and outcomes.

This strategic expansion is built upon a formidable foundation. RoboCT’s medical-grade exoskeletons are among the first in China to receive NMPA certification for neurological rehabilitation. The company boasts a robust intellectual property portfolio of over 500 patents and has led the formulation of multiple national and industry standards for exoskeleton robots. Its new manufacturing base in Wuxi is designed to scale production for consumer-grade products like the GoGo series, ensuring high performance at accessible costs.

Looking to the future, RoboCT articulates a bold “Human+” vision. The company is actively exploring applications that transcend traditional healthcare, including industrial support to prevent worker injury, wellness solutions for active aging, and performance enhancement for outdoor recreation. RoboCT envisions a world where exoskeleton technology, through continuous miniaturization and intelligence, becomes a seamless, low-risk enhancement to human capability—an intuitive “new organ” for the modern era.

By presenting its ecosystem strategy at CES, RoboCT positions itself at the forefront of a broader industry evolution. The company is not merely selling devices but is advocating for and building a future where robotic assistance is normalized, enhancing quality of life, productivity, and human potential on a global scale.

About RoboCT:

Founded in 2017, RoboCT is a national high-tech enterprise with technological innovation as the core driving force. RoboCT is dedicated to the R&D and application of exoskeleton robotics, mainly in terms of core algorithms and components. Rehabilitation and elderly care are the current main focus, and RoboCT provides intelligent products and solutions for both medical institutions and individuals, based on a combined technology of human-computer interaction, artificial intelligence, data analysis, and cloud computing.

Media Contact:

Brenda GUAN Mengqi
Public Relations Manager
guanmengqi@roboct.com
web: en.roboct.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/from-clinical-recovery-to-lifelong-empowerment-roboct-showcases-integrated-ecosystem-strategy-at-ces-2026-302657548.html

SOURCE RoboCT

Market Opportunity
Whalebit Logo
Whalebit Price(CES)
$0.8427
$0.8427$0.8427
+1.73%
USD
Whalebit (CES) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Approval Rating Tracker: 39% In Latest Survey

Trump Approval Rating Tracker: 39% In Latest Survey

The post Trump Approval Rating Tracker: 39% In Latest Survey appeared on BitcoinEthereumNews.com. Sept. 16-18 net approval rating: Trump’s favorability rating declined three points to 39% and the share of U.S. adults who have an unfavorable view of him increased two points to 57% compared to last week in an Economist/YouGov survey of 1,567 U.S. adults conducted Sept. 12-15 (margin of error 3.6). The results represent an 11-point decline in Trump’s 50% favorability rating at the start of his term, according to Economist/YouGov polling. Sept. 15-6 net approval rating: Trump’s job performance improved one point, to 46%, in Morning Consult’s weekly survey compared to the previous week, while his disapproval rating stayed stagnant at 52% (the poll of 2,204 registered U.S. voters was conducted Sept. 12-14 and has a margin of error of 2). The poll found the killing of conservative activist Charlie Kirk is the top story of 2025, with 67% of voters saying they’ve seen, read or heart “a lot” about it, according to Morning Consult, well above hundreds of other news events Morning Consult has asked about this year. Sept. 10-14: On par with two other polls this week, Trump had a 42% approval rating in the latest Reuters/Ipsos survey conducted Sept. 5-9, while 56% disapproved, representing a two-point increase from the groups’ August poll in his disapproval rating and a two-point uptick in his approval rating (the poll of 1,084 U.S. adults has a margin of error of 3). Sept. 8-7: Trump’s approval rating declined one point from last week, to 45%, tied with his record low since taking office, according to Morning Consult’s weekly survey that found 52% disapprove of his job performance (the poll of 2,201 registered voters conducted Sept. 6-8 has a margin of error of 2). Sept. 7-12: Trump’s approval rating ticked up two points from July, to 44%, while his disapproval rating declined two…
Share
BitcoinEthereumNews2025/09/18 01:08
Solo Bitcoin Miner Wins $210K After 1-in-28,000 Odds

Solo Bitcoin Miner Wins $210K After 1-in-28,000 Odds

A solo Bitcoin miner beat roughly 1-in-28,000 odds to mine a block through Solo CKPool, turning a tiny hash rate into a reward worth about $210,000.
Share
coinlineup2026/04/06 14:58
Payward Names Robert Moore as Chief Financial Officer

Payward Names Robert Moore as Chief Financial Officer

Payward announced the appointment of Robert Moore as Chief Financial Officer, effective immediately. Most executive searches answer the question in front of them
Share
Globalfintechseries2026/04/06 15:16

$30,000 in PRL + 15,000 USDT

$30,000 in PRL + 15,000 USDT$30,000 in PRL + 15,000 USDT

Deposit & trade PRL to boost your rewards!